Intellia Therapeutics Inc (NTLA)

[Frankestin]

So let me get this straight — enrollment done in 9 months, RMAT in hand, a one-shot CRISPR therapy showing near-functional cure signals, a 2026 BLA already lined up and a 2027 launch in sight… and they’re even pulling forward a conference to talk about it — but sure, nothing special here.
The only ‘risk’ is expectations running so high that someone tries to spoil the party… when what’s already on the table should be enough to surprise.
And if this gets any form of fast-track or accelerated push on top of that? This doesn’t grind higher — it explodes.